Heart attack

Natural product-derived therapy for attenuating pathogenesis-associated with Myocardial infarction: A pharmaceutical mixture encompassing Sulforaphane, Myricitrin, and Aspalathin (SMA) decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflmmatory cells, inhibits ventricular dilation, and promotes heart repair and survival via up regulation of its target gene, 11/January/2017, 11.48 pm
Natural product-derived therapy for attenuating pathogenesis-associated with Myocardial infarction: A pharmaceutical mixture encompassing Sulforaphane, Myricitrin, and Aspalathin (SMA) decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflmmatory cells, inhibits ventricular dilation, and promotes heart repair and survival via up regulation of its target gene, 11/January/2017, 11.48 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA; and Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston,…

read more

Vitamin-based therapy for improving cardiac contractility and attenuating pathogenesis-associated with Myocardial infarction:   Phytonadione/Mephyton/VitaminK1  decreases GRK2 (G Protein-Coupled Receptor Kinase 2) and GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, increases cardiac contractility, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, promotes heart healing and inhibits glucose intolerance, via up regulation of its target gene, 4/January/2017, 6.17 am
Vitamin-based therapy for improving cardiac contractility and attenuating pathogenesis-associated with Myocardial infarction:   Phytonadione/Mephyton/VitaminK1  decreases GRK2 (G Protein-Coupled Receptor Kinase 2) and GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, increases cardiac contractility, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, promotes heart healing and inhibits glucose intolerance, via up regulation of its target gene, 4/January/2017, 6.17 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study, from Department of Medicine, Division of Cardiology, Dept of Cell Biology, and Department of Molecular Genetics, Duke University Medical Center, Durham, North Carolina,…

read more

Molecular therapy for Cardiomyopathy: A pharmacological mixture encompassing VitaminK1 (Phytonadione/Mephyton) and Asprin (VKASP) decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene, 4/January/2018,  5.48 am
Molecular therapy for Cardiomyopathy: A pharmacological mixture encompassing VitaminK1 (Phytonadione/Mephyton) and Asprin (VKASP) decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene, 4/January/2018,  5.48 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say   A study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA shows that “Trbp regulates heart function through microRNA-mediated Sox6 repression.” This…

read more

Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients:  A pharmaceutical mixture [PMEET] encompassing Pyridoxamine (PM-a form of Vitamin-B (6)) and 14, 15 Epoxyeicosatrienoic acid (14, 15-EET)  increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down regulation of its target gene, 26/December/2017, 11.49 pm
Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients:  A pharmaceutical mixture [PMEET] encompassing Pyridoxamine (PM-a form of Vitamin-B (6)) and 14, 15 Epoxyeicosatrienoic acid (14, 15-EET)  increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down regulation of its target gene, 26/December/2017, 11.49 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was published, in the 6 April…

read more

Combinatorial therapy for improving cardiac contractility and attenuating pathogenesis associated with Myocardial infarction: A pharmaceutical mixture encompassing Matrine, Epicatechin, 14, 15, Epoxyeicosatrienoicacids (14, 15 EETs) (MEEET)  decreases GRK2 (G Protein-Coupled Receptor Kinase 2) and GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, increases cardiac contractility, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, promotes heart healing and inhibits glucose intolerance, via up regulation of its target gene, 25/December/2017, 1.37 am
Combinatorial therapy for improving cardiac contractility and attenuating pathogenesis associated with Myocardial infarction: A pharmaceutical mixture encompassing Matrine, Epicatechin, 14, 15, Epoxyeicosatrienoicacids (14, 15 EETs) (MEEET)  decreases GRK2 (G Protein-Coupled Receptor Kinase 2) and GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, increases cardiac contractility, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, promotes heart healing and inhibits glucose intolerance, via up regulation of its target gene, 25/December/2017, 1.37 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study, from Department of Medicine, Division of Cardiology, Dept of Cell Biology, and Department of Molecular Genetics, Duke University Medical Center, Durham, North Carolina,…

read more

Molecular therapy for Cardiomyopathy: Lycopene (LYC), isolated from Gac, Guava, and Tomatoes, among others, decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene, 24/December/2017,  12.51 am
Molecular therapy for Cardiomyopathy: Lycopene (LYC), isolated from Gac, Guava, and Tomatoes, among others, decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene, 24/December/2017,  12.51 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say   A study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA shows that “Trbp regulates heart function through microRNA-mediated Sox6 repression.” This…

read more
Start Typing